GLUE - Monte Rosa Therapeutics, Inc. Stock Price, Fair Value and News

$16.85+1.44 (+9.34%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GLUE Price Action

Last 7 days

5.4%

Last 30 days

39.6%

Last 90 days

243.2%

Trailing 12 Months

70.9%

GLUE RSI Chart

GLUE Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

52.38

Price/Sales (Trailing)

6.04

EV/EBITDA

29.23

Price/Free Cashflow

7.57

GLUE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GLUE Fundamentals

GLUE Revenue

Revenue (TTM)

181.5M

Rev. Growth (Yr)

38.54%

Rev. Growth (Qtr)

-44.95%

GLUE Earnings

Earnings (TTM)

20.9M

Earnings Growth (Yr)

-13.5%

Earnings Growth (Qtr)

-120.26%

GLUE Profitability

EBT Margin

12.09%

Return on Equity

8.52%

Return on Assets

4.56%

Free Cashflow Yield

13.22%

GLUE Investor Care

Shares Dilution (1Y)

6.09%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	159.5M	178.0M	181.5M	0
2024	0	0	0	75.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

CEO	Dr. Markus Warmuth M.D.
WEBSITE	monterosatx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	133

Monte Rosa Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Monte Rosa Therapeutics, Inc.? What does GLUE stand for in stocks?

GLUE is the stock ticker symbol of Monte Rosa Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Monte Rosa Therapeutics, Inc. (GLUE)?

As of Wed Dec 03 2025, market cap of Monte Rosa Therapeutics, Inc. is 1.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLUE stock?

You can check GLUE's fair value in chart for subscribers.

Is Monte Rosa Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GLUE is over valued or under valued. Whether Monte Rosa Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Monte Rosa Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLUE.

What is Monte Rosa Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, GLUE's PE ratio (Price to Earnings) is 52.38 and Price to Sales (PS) ratio is 6.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GLUE PE ratio will change depending on the future growth rate expectations of investors.